vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and WESBANCO INC (WSBC). Click either name above to swap in a different company.
WESBANCO INC is the larger business by last-quarter revenue ($257.2M vs $180.9M, roughly 1.4× AVANOS MEDICAL, INC.). WESBANCO INC runs the higher net margin — 34.5% vs -0.7%, a 35.2% gap on every dollar of revenue. Over the past eight quarters, WESBANCO INC's revenue compounded faster (31.9% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
WesBanco, Inc., is a bank holding company headquartered in Wheeling, West Virginia, United States. It has over 200 branches in West Virginia, Ohio, Western Pennsylvania, Kentucky, Maryland, and Southern Indiana.
AVNS vs WSBC — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $257.2M |
| Net Profit | $-1.3M | $88.6M |
| Gross Margin | 47.5% | — |
| Operating Margin | 1.4% | — |
| Net Margin | -0.7% | 34.5% |
| Revenue YoY | 0.7% | — |
| Net Profit YoY | 99.7% | 54.4% |
| EPS (diluted) | $-0.02 | $0.88 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $257.2M | ||
| Q4 25 | $180.9M | $265.6M | ||
| Q3 25 | $177.8M | $261.6M | ||
| Q2 25 | $175.0M | $260.7M | ||
| Q1 25 | $167.5M | $193.2M | ||
| Q4 24 | $179.6M | $162.9M | ||
| Q3 24 | $170.4M | $150.8M | ||
| Q2 24 | $171.7M | $147.9M |
| Q1 26 | — | $88.6M | ||
| Q4 25 | $-1.3M | $91.1M | ||
| Q3 25 | $-1.4M | $83.6M | ||
| Q2 25 | $-76.8M | $57.4M | ||
| Q1 25 | $6.6M | $-9.0M | ||
| Q4 24 | $-397.3M | $49.6M | ||
| Q3 24 | $4.3M | $37.3M | ||
| Q2 24 | $1.8M | $28.9M |
| Q1 26 | — | — | ||
| Q4 25 | 47.5% | — | ||
| Q3 25 | 48.4% | — | ||
| Q2 25 | 52.6% | — | ||
| Q1 25 | 53.6% | — | ||
| Q4 24 | 54.6% | — | ||
| Q3 24 | 54.5% | — | ||
| Q2 24 | 55.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.4% | 43.2% | ||
| Q3 25 | 0.1% | 39.5% | ||
| Q2 25 | -42.6% | 27.2% | ||
| Q1 25 | 6.1% | -5.0% | ||
| Q4 24 | -233.0% | 38.0% | ||
| Q3 24 | 7.0% | 29.7% | ||
| Q2 24 | 3.7% | 23.7% |
| Q1 26 | — | 34.5% | ||
| Q4 25 | -0.7% | 34.3% | ||
| Q3 25 | -0.8% | 31.9% | ||
| Q2 25 | -43.9% | 22.0% | ||
| Q1 25 | 3.9% | -4.7% | ||
| Q4 24 | -221.2% | 30.5% | ||
| Q3 24 | 2.5% | 24.7% | ||
| Q2 24 | 1.0% | 19.5% |
| Q1 26 | — | $0.88 | ||
| Q4 25 | $-0.02 | $0.97 | ||
| Q3 25 | $-0.03 | $0.84 | ||
| Q2 25 | $-1.66 | $0.57 | ||
| Q1 25 | $0.14 | $-0.15 | ||
| Q4 24 | $-8.64 | $0.72 | ||
| Q3 24 | $0.09 | $0.54 | ||
| Q2 24 | $0.04 | $0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | — |
| Total DebtLower is stronger | $90.3M | — |
| Stockholders' EquityBook value | $778.2M | $4.1B |
| Total Assets | $1.1B | $27.5B |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $89.8M | $956.1M | ||
| Q3 25 | $70.5M | $1.0B | ||
| Q2 25 | $90.3M | $1.2B | ||
| Q1 25 | $97.0M | $1.1B | ||
| Q4 24 | $107.7M | $568.1M | ||
| Q3 24 | $89.0M | $620.9M | ||
| Q2 24 | $92.2M | $486.8M |
| Q1 26 | — | — | ||
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — |
| Q1 26 | — | $4.1B | ||
| Q4 25 | $778.2M | $4.0B | ||
| Q3 25 | $778.0M | $4.1B | ||
| Q2 25 | $776.3M | $3.8B | ||
| Q1 25 | $839.4M | $3.8B | ||
| Q4 24 | $828.5M | $2.8B | ||
| Q3 24 | $1.2B | $2.8B | ||
| Q2 24 | $1.2B | $2.5B |
| Q1 26 | — | $27.5B | ||
| Q4 25 | $1.1B | $27.7B | ||
| Q3 25 | $1.1B | $27.5B | ||
| Q2 25 | $1.0B | $27.6B | ||
| Q1 25 | $1.1B | $27.4B | ||
| Q4 24 | $1.2B | $18.7B | ||
| Q3 24 | $1.7B | $18.5B | ||
| Q2 24 | $1.7B | $18.1B |
| Q1 26 | — | — | ||
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | — |
| Free Cash FlowOCF − Capex | $21.3M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 3.8% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $28.2M | $290.4M | ||
| Q3 25 | $14.0M | $116.9M | ||
| Q2 25 | $6.8M | $105.0M | ||
| Q1 25 | $25.7M | $-26.4M | ||
| Q4 24 | $57.9M | $211.0M | ||
| Q3 24 | $23.0M | $60.7M | ||
| Q2 24 | $27.8M | $18.2M |
| Q1 26 | — | — | ||
| Q4 25 | $21.3M | $280.0M | ||
| Q3 25 | $7.0M | $114.9M | ||
| Q2 25 | $-4.2M | $98.3M | ||
| Q1 25 | $19.0M | $-30.7M | ||
| Q4 24 | $53.1M | $200.7M | ||
| Q3 24 | $20.0M | $56.9M | ||
| Q2 24 | $21.9M | $17.3M |
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | 105.4% | ||
| Q3 25 | 3.9% | 43.9% | ||
| Q2 25 | -2.4% | 37.7% | ||
| Q1 25 | 11.3% | -15.9% | ||
| Q4 24 | 29.6% | 123.2% | ||
| Q3 24 | 11.7% | 37.7% | ||
| Q2 24 | 12.8% | 11.7% |
| Q1 26 | — | — | ||
| Q4 25 | 3.8% | 3.9% | ||
| Q3 25 | 3.9% | 0.8% | ||
| Q2 25 | 6.3% | 2.6% | ||
| Q1 25 | 4.0% | 2.2% | ||
| Q4 24 | 2.7% | 6.3% | ||
| Q3 24 | 1.8% | 2.5% | ||
| Q2 24 | 3.4% | 0.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.19× | ||
| Q3 25 | — | 1.40× | ||
| Q2 25 | — | 1.83× | ||
| Q1 25 | 3.89× | — | ||
| Q4 24 | — | 4.25× | ||
| Q3 24 | 5.35× | 1.63× | ||
| Q2 24 | 15.44× | 0.63× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
WSBC
| Net Interest Income | $215.4M | 84% |
| Noninterest Income | $41.8M | 16% |
